A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects With Advanced Tumors

Trial Profile

A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects With Advanced Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs BGB A317 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors BeiGene
  • Most Recent Events

    • 12 Sep 2017 Preliminary results from a subset of patients with advanced ovarian cancer (As of 6 Mar 2017; n=51) presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Preliminary results (n=55) related to a subset of patients with advanced gastric cancer (GC) and esophageal carcinoma (EC) were presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Preliminary results (n=18) related to a subset of patients with advanced head and neck squamous cell cancer (HNSCC) were presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top